These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11447097)

  • 1. Niacin after coronary bypass grafting and for coronary disease prevention.
    Parsons WB
    Circulation; 2001 Jul; 104(2):E7. PubMed ID: 11447097
    [No Abstract]   [Full Text] [Related]  

  • 2. Antioxidants blunt high-density lipoprotein response to statin plus niacin therapy.
    Kris-Etherton PM
    Curr Atheroscler Rep; 2001 Nov; 3(6):435-6. PubMed ID: 11602062
    [No Abstract]   [Full Text] [Related]  

  • 3. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
    Sposito AC; Mansur AP; Maranhão RC; Rodrigues-Sobrinho CR; Coelho OR; Ramires JA
    Braz J Med Biol Res; 2001 Feb; 34(2):177-82. PubMed ID: 11175492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.
    Sacks FM
    Am J Cardiol; 2001 Dec; 88(12A):14N-18N. PubMed ID: 11788125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
    Scanu AM; Bamba R
    Am J Cardiol; 2008 Apr; 101(8A):44B-47B. PubMed ID: 18375241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of simvastatin-niacin and antioxidant therapy on HDL.
    Drown DJ
    Prog Cardiovasc Nurs; 2002; 17(2):102-3. PubMed ID: 11986546
    [No Abstract]   [Full Text] [Related]  

  • 8. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
    Boden WE; Pearson TA
    Am J Cardiol; 2000 Mar; 85(5):645-50, A10. PubMed ID: 11078282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid disorders.
    Kole LA
    JAAPA; 2009 Nov; 22(11):54-5. PubMed ID: 19999177
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations.
    Sacks FM;
    Am J Cardiol; 2002 Jul; 90(2):139-43. PubMed ID: 12106843
    [No Abstract]   [Full Text] [Related]  

  • 11. What can I do to lower my lipoprotein(a) level?
    Heart Advis; 2008 Apr; 11(4):8. PubMed ID: 18697235
    [No Abstract]   [Full Text] [Related]  

  • 12. [Niacin--an additive therapeutic approach for optimizing lipid profile].
    Wieneke H; Schmermund A; Erbel R
    Med Klin (Munich); 2005 Apr; 100(4):186-92. PubMed ID: 15834527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triglyceride as a risk factor for coronary artery disease.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiatherothrombotic effects of nicotinic acid.
    Rosenson RS
    Atherosclerosis; 2003 Nov; 171(1):87-96. PubMed ID: 14642410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes.
    Pan J; Lin M; Kesala RL; Van J; Charles MA
    Diabetes Obes Metab; 2002 Jul; 4(4):255-61. PubMed ID: 12099974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of extended-release niacin on lipoprotein subclass distribution.
    Morgan JM; Capuzzi DM; Baksh RI; Intenzo C; Carey CM; Reese D; Walker K
    Am J Cardiol; 2003 Jun; 91(12):1432-6. PubMed ID: 12804729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What is the future for niacin after the AIM-HIGH study?].
    Cybulska B; Kłosiewicz Latoszek L
    Kardiol Pol; 2012; 70(3):315-6. PubMed ID: 22430425
    [No Abstract]   [Full Text] [Related]  

  • 20. LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?
    Taskinen MR
    Diabetes Res Clin Pract; 2003 Jul; 61 Suppl 1():S19-26. PubMed ID: 12880691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.